ArticleCardio-oncology (London, England)2025
Integrative speckle-tracking echocardiography for the early detection and prediction of cancer therapy-related cardiac dysfunction.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Balancing Oncological Care and Quality of Life: Diagnostic and Therapeutic Strategies for Chemotherapy-Induced Cardiotoxicity-A Narrative Review.Journal of clinical medicine · 2026Review
- Imaging in Cardio-Oncology: Role of Novel Echo Parameters in Breast Cancer and Gynecologic Malignancies.Current cardiology reports · 2026Review
- Correction: Integrative speckle-tracking echocardiography for the early detection and prediction of cancer therapy-related cardiac dysfunction.Cardio-oncology (London, England) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
Abstract
backgroundThe cancer therapy–related cardiac dysfunction (CTRCD) induced by anthracycline could involve the whole heart. However, the overall changes of strain parameters, including the atrial and right heart strains, myocardial work, along with the established left ventricular global longitudinal strain (GLS), during cancer therapy, remain unclear.
methodsIn this prospective cohort study, 83 women undergoing anthracycline treatment for breast cancer, underwent serial echocardiographic examinations at baseline (pre-chemotherapy, T0), after 1 to 4 cycles (T1-T4) and 3 months after treatment completion (T5). Speckle tracking echocardiography (STE) derived parameters, including GLS, left atrial strains, right heart strains and myocardial work indices, were measured. CTRCD was defined as a relative reduction of > 15% in GLS from baseline or severer cardiac impairments according to current joint guidelines. Generalized estimating equations quantified the association between changes in strain parameters and anthracycline-induced CTRCD. Univariate logistic regression and receiver operating characteristic curves were used to explore the combined values of identified strain parameters for the prediction of CTRCD.
resultsTwenty-five (30.1%) patients developed CTRCD during the serial examinations. Compared with baseline, significant declines in GLS, left atrial reservoir strain (LASr), left atrial conduit strain (LAScd), global work index (GWI) and global constructive work (GCW) were observed at T1. For trajectories analysis, GLS, LASr, LAScd, left atrial total emptying fraction, GWI and GCW were different between patients with and without CTRCD (all P < 0.05). The relative changes of GLS, LASr, GWI at T1 were identified as predictors of CTRCD, with improved predictive value when combined together.
conclusionNot only the GLS, but also the LASr and myocardial work indices were significantly impaired just after one cycle therapy of anthracycline. The integrative STE could serve as an early detective and predictive approach for CTRCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.